Funded Startups in North Lanarkshire
Seven funded companies are listed for North Lanarkshire, spanning round dates from 2021-09-06 (ILC Therapeutics) to 2023-09-13 (Mironid).
Seven funded companies are listed for North Lanarkshire, spanning round dates from 2021-09-06 (ILC Therapeutics) to 2023-09-13 (Mironid). The largest disclosed round is Mironid’s $38M Series A on 2023-09-13, which dwarfs the next-largest disclosed amounts in the table ($9M for PneumoWave on 2023-01-12, $6M for IbisVision on 2023-05-11, and $5M for ILC Therapeutics on 2021-09-06). Most disclosed amounts cluster at mid-single to high-single digits, with $4M (TC BioPharm on 2022-06-02) and $6M (IbisVision) sitting below PneumoWave’s $9M.
Biotechnology is the dominant sector across the rows (4 of 7: IbisVision, Amphista Therapeutics, TC BioPharm, ILC Therapeutics), and at least three entries have non-disclosed or non-standard stage labeling (“Series Unknown” appears 3 times, and one row is “undisclosed”). Geographically, entries concentrate in Newhouse (Mironid, IbisVision, ILC Therapeutics), with additional activity in Motherwell (GCM Recruitment, PneumoWave, Amphista Therapeutics) and a smaller cluster in Holytown (TC BioPharm).
Most recent rounds
7 shownRelated listings
Frequently asked
Which disclosed round is the outlier in North Lanarkshire, and how does it compare to the other disclosed amounts?
Mironid’s $38M Series A on 2023-09-13 is the standout outlier: the next-largest disclosed amount in the table is $9M (PneumoWave on 2023-01-12), with other disclosed figures landing at $6M (IbisVision, 2023-05-11), $5M (ILC Therapeutics, 2021-09-06), and $4M (TC BioPharm, 2022-06-02).
Are certain cities or sectors over-represented among these most recent entries?
Newhouse shows up three times (Mironid on 2023-09-13, IbisVision on 2023-05-11, ILC Therapeutics on 2021-09-06), more than Motherwell (three entries: GCM Recruitment 2023-05-02, PneumoWave 2023-01-12, Amphista Therapeutics 2022-12-13) and Holytown (one entry: TC BioPharm, 2022-06-02). Sector-wise, biotechnology appears 4 of 7 times (IbisVision 2023-05-11, Amphista Therapeutics 2022-12-13, TC BioPharm 2022-06-02, ILC Therapeutics 2021-09-06).
What does the stage label mix look like in this table, including undisclosed amounts?
Stage labeling is frequently not specific: “Series Unknown” appears 3 times (IbisVision $6M on 2023-05-11, GCM Recruitment undisclosed on 2023-05-02, and ILC Therapeutics $5M on 2021-09-06), and one additional row is explicitly “undisclosed” (GCM Recruitment, 2023-05-02). Disclosed amounts also span multiple labeled stages: Series A (Mironid $38M on 2023-09-13; PneumoWave $9M on 2023-01-12) plus Series B (Amphista Therapeutics is listed as “undisclosed” on 2022-12-13).
How concentrated are the rounds over time among these seven entries?
The most recent three rounds fall within a 4-month window: Mironid ($38M) on 2023-09-13, IbisVision ($6M) on 2023-05-11, and GCM Recruitment (undisclosed) on 2023-05-02, with PneumoWave ($9M) following earlier at 2023-01-12. The overall date span is 2021-09-06 to 2023-09-13, indicating the table is backfilled beyond the newest year but still concentrated in the 2021–2023 period.
Which entries have undisclosed amounts, and do they affect the apparent funding size pattern?
Two entries show undisclosed economics: GCM Recruitment is “undisclosed” on 2023-05-02, and Amphista Therapeutics is “undisclosed” despite being listed as a Series B on 2022-12-13. Because the remaining disclosed rounds range from $4M to $38M (e.g., TC BioPharm $4M on 2022-06-02 vs Mironid $38M on 2023-09-13), the undisclosed rows limit precision around the mid-range but don’t change the fact that Mironid’s $38M is far above the other disclosed figures.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.